CAJ | 학술논문

目的：观察基质细胞衍生因子1‐α（stromal cell derived factor 1‐α，SDF1‐α）受体抑制剂AMD3100联用索拉非尼对肝细胞肝癌（HCC）裸鼠的疗效。方法：建立肝细胞肝癌原位裸鼠模型，分为对照组、索拉非尼组、索拉非尼＋ AMD3100组，每组6只。索拉非尼组给予索拉非尼30 mg／（kg · d）灌胃；索拉非尼＋ AMD3100组在给予索拉非尼灌胃的基础上，给予AMD31002．5 mg／（kg · d）腹腔注射；对照组给予0．9％氯化钠液灌胃。比较三组的肿瘤肝内播散情况、肿瘤大小、肺转移情况和裸鼠的生存时间。结果：在索拉非尼治疗的基础上，联用AMD3100能够明显抑制索拉非尼引起的 HCC肝内侵袭和转移，进一步减小肿瘤体积，减少肺转移，延长荷瘤裸鼠的生存期。结论：SDF1‐α受体抑制剂AMD3100能够增强索拉非尼对HCC的疗效。
목적：관찰기질세포연생인자1‐α（stromal cell derived factor 1‐α，SDF1‐α）수체억제제AMD3100련용색랍비니대간세포간암（HCC）라서적료효。방법：건립간세포간암원위라서모형，분위대조조、색랍비니조、색랍비니＋ AMD3100조，매조6지。색랍비니조급여색랍비니30 mg／（kg · d）관위；색랍비니＋ AMD3100조재급여색랍비니관위적기출상，급여AMD31002．5 mg／（kg · d）복강주사；대조조급여0．9％록화납액관위。비교삼조적종류간내파산정황、종류대소、폐전이정황화라서적생존시간。결과：재색랍비니치료적기출상，련용AMD3100능구명현억제색랍비니인기적 HCC간내침습화전이，진일보감소종류체적，감소폐전이，연장하류라서적생존기。결론：SDF1‐α수체억제제AMD3100능구증강색랍비니대HCC적료효。
Objective:To investigate the effect of AMD3100 ,an inhibitor of receptor of stromal cell derived factor 1‐α (SDF1‐α) ,combined with sorafenib on nude mice with hepatocellular carcinoma (HCC) .Methods:Nude mice models of HCC in situ was established and the mice were divided into control group ,sorafenib group and sorafenib combined with AMD3100 group , with six mice in each group .In sorafenib group ,sorafenib 30 mg/(kg · d) was given by garage .In sorafenib combined with AMD3100 group ,AMD3100 2 .5 mg/(kg · d) was administrated by intraperitoneal injection based on the method of sorafenib group .In the control group ,0 .9% sodium chloride solution was given by garage . The intrahepatic invasion , the tumor volume ,the situation of pulmonary metastasis and the survival time of nude mice ,were compared among the three groups . Results:When sorafenib was combined with AMD3100 ,the intrahepatic invasion and metastasis of HCC caused by sorafenib could be significantly inhibited .Thus the tumor volume was decreased and the pulmonary metastasis could be reduced .The survival time was prolonged .Conclusions:AMD3100 ,a SDF1‐α receptor inhibitor ,can enhance the efficacy of sorafenib .